hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06312878, orgStudyIdInfo id: IRBN052024/CHUSTE, briefTitle: CT Features of Interrupted Inferior Vena Cava With Azygous Continuation, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2024-03-31, completionDateStruct date: 2024-03-31, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Centre Hospitalier Universitaire de Saint Etienne, class: OTHER, descriptionModule briefSummary: Inferior vena cava (IVC) is the largest vein is the body, draining blood from the abdomen, pelvis and lower extremities. IVC anomalies can be congenital or acquired.The origins of these anomalies are not entirely clear, and their incidence is uncertain.Imaging plays a pivotal role in diagnosis to prevent misinterpretation. CT scan is a quick, available, and suitable imaging modality in emergency setting.The aim of this retrospective monocentric study was of describe CT features of interrupted suprarenal inferior vena cava with azygous continuation., conditionsModule conditions: Anatomical Variant of the Inferior Vena Cava, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 10, type: ESTIMATED, armsInterventionsModule interventions name: Describe the anatomy of the IVC in the case of an anatomical variant, outcomesModule primaryOutcomes measure: Describe CT features of interrupted suprarenal inferior vena cava with azygous continuation, secondaryOutcomes measure: Describe CT features of interrupted suprarenal inferior vena cava with azygous continuation, secondaryOutcomes measure: Describe association with polysplenic syndrome, secondaryOutcomes measure: Describe association with polysplenic syndrome, secondaryOutcomes measure: Describe association with polysplenic syndrome, secondaryOutcomes measure: Describe association with polysplenic syndrome, secondaryOutcomes measure: Describe association with polysplenic syndrome, secondaryOutcomes measure: Describe association with polysplenic syndrome, secondaryOutcomes measure: Describe circumstances of discovering the interrupted IVC, secondaryOutcomes measure: Describe circumstances of discovering the interrupted IVC, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: CHU de Saint-Etienne, status: RECRUITING, city: Saint-Priest-en-Jarez, zip: 42270, country: France, contacts name: Sylvain Grange, MD, role: CONTACT, phone: (0)477829066, phoneExt: +33, email: grangesylvain@hotmail.fr, contacts name: Sylvain Grange, MD, role: PRINCIPAL_INVESTIGATOR, contacts name: Rémi Grange, MD, role: SUB_INVESTIGATOR, geoPoint lat: 45.47501, lon: 4.37614, hasResults: False
protocolSection identificationModule nctId: NCT06312865, orgStudyIdInfo id: IXTEGYPT, briefTitle: Intermittent Exotropia in Egyptian Population, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2025-07, completionDateStruct date: 2025-11, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Assiut University, class: OTHER, descriptionModule briefSummary: Strabismus is one of the most frequent ocular problems among developmentally normal children. The prevalence of strabismus varies among different regions, ranging from 0.06% in Japan to 5.65% in China. Exotropia is reported to be the most prevalent type of deviation in many of these studies. About 48-92% of the exotropic patients have intermittent exotropia (IXT). Jenkins reported that the prevalence of exodeviation was higher in countries near the Equator. Its prevalence is also higher in subequatorial Africa, the Middle East, and East Asia (where there is plenty of sunshine) in comparison to the USA and Central Europe. Intermittent exotropia is a disorder of binocular eye movement control, where one eye intermittently turns outward. The outward deviation is greatest and likely occurs at far distances viewing, when the oculomotor convergence effort is weakest, and occurs frequently when the patient is under stress, tired, ill, or in particular test situations. X(T) can also occur at near as convergence insufficiency., conditionsModule conditions: Exotropia, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 600, type: ESTIMATED, armsInterventionsModule interventions name: Ophthalmic exam, outcomesModule primaryOutcomes measure: The difference in demographic criteria in Egyptian population, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06312852, orgStudyIdInfo id: Antenatal steroids & clotting, briefTitle: Impact of Antenatal Steroids on Coagulation., statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2025-04, completionDateStruct date: 2025-05, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Assiut University, class: OTHER, descriptionModule briefSummary: Aim of the research :1- Detection of the presence or absence of any effect of antenatal corticosteroid administration on coagulopathy, fibrinolysis, and other haematological markers., conditionsModule conditions: Corticosteroids Adverse Reaction, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: PROSPECTIVE, enrollmentInfo count: 45, type: ESTIMATED, outcomesModule primaryOutcomes measure: Antenatal corticosteroids impact on Coagulopathy, secondaryOutcomes measure: Follow up for cases on corticosteroid therapy, eligibilityModule sex: FEMALE, minimumAge: 15 Years, maximumAge: 45 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06312839, orgStudyIdInfo id: IRBN032024/CHUSTE, briefTitle: Preoperative Arterial Embolization Before Oncologic Esophagectomy as a Technique for Ischemic Gastric Conditioning, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2025-12, completionDateStruct date: 2025-12, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Centre Hospitalier Universitaire de Saint Etienne, class: OTHER, descriptionModule briefSummary: This retrospective monocentric comparative study aims to assess the efficacy of preoperative ischemic conditioning, in preventing anastomotic leakage in esophageal cancer surgery. Two groups were included : a surgery-alone group (control group) and a PreopAE group (study group) treated with an embolization procedure before esophagectomy. Collected data included patient characteristics, embolization procedure details, surgical outcomes, and postoperative complications.The primary outcome was the efficacy of preoperative ischemic conditioning in preventing anastomotic leakage, assessed through CT scans. Secondary outcomes included analyzing safety of ischemic gastric conditioning, hypertrophy of the gastroepiploic artery in embolized patients and comparing hospital stay length and postoperative mortality., conditionsModule conditions: Esophageal Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Collecting data from the medical record, outcomesModule primaryOutcomes measure: Measurement of the effectiveness of preoperative ischaemic conditioning in reducing anastomotic leakage in patients undergoing oesophagectomy., secondaryOutcomes measure: Measurement of the effectiveness of preoperative ischaemic conditioning in reducing anastomotic leakage in patients undergoing oesophagectomy., secondaryOutcomes measure: Measurement of the effectiveness of preoperative ischaemic conditioning in reducing anastomotic leakage in patients undergoing oesophagectomy., secondaryOutcomes measure: Safety of ischemic gastric conditioning, secondaryOutcomes measure: Hypertrophy of the gastroepiploic artery, secondaryOutcomes measure: Comparing hospital stay length, secondaryOutcomes measure: Comparing postoperative mortality, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: CHU de Saint-Etienne, city: Saint-Priest-en-Jarez, zip: 42270, country: France, contacts name: Rémi Grange, MD, role: CONTACT, contacts name: Sylvain Grange, MD, role: SUB_INVESTIGATOR, contacts name: Rémi Grange, MD, role: PRINCIPAL_INVESTIGATOR, contacts name: Zoé Sahut, resident, role: SUB_INVESTIGATOR, geoPoint lat: 45.47501, lon: 4.37614, hasResults: False
protocolSection identificationModule nctId: NCT06312813, orgStudyIdInfo id: 2023-296, briefTitle: Evaluating Use of Topical Imipramine and Amitriptyline in Reducing Ultraviolet B Light-Induced Redness in Patients With Rosacea, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-27, primaryCompletionDateStruct date: 2028-12, completionDateStruct date: 2028-12, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Wright State University, class: OTHER, descriptionModule briefSummary: Rosacea is a common skin condition associated with easy blushing and red face; many patients with rosacea react to sunlight with increased redness. The purpose of this study is to determine if the use of a topical medication will help reduce sunlight induced redness and irritation in patients with rosacea., conditionsModule conditions: Rosacea, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 48, type: ESTIMATED, armsInterventionsModule interventions name: Imipramine, interventions name: Amitriptyline, interventions name: Vehicle, outcomesModule primaryOutcomes measure: Ultraviolet B induced erythema change with 4% imipramine, primaryOutcomes measure: Ultraviolet B induced erythema change with 4% imipramine, primaryOutcomes measure: Ultraviolet B induced erythema change with 4% imipramine, primaryOutcomes measure: Ultraviolet B induced erythema change with 4% imipramine, primaryOutcomes measure: Ultraviolet B induced erythema change with 4% amitriptyline, primaryOutcomes measure: Ultraviolet B induced erythema change with 4% amitriptyline, primaryOutcomes measure: Ultraviolet B induced erythema change with 4% amitriptyline, primaryOutcomes measure: Ultraviolet B induced erythema change with 4% amitriptyline, secondaryOutcomes measure: Tolerability of 4% imipramine on facial skin, secondaryOutcomes measure: Tolerability of 4% imipramine on facial skin, secondaryOutcomes measure: Tolerability of 4% imipramine on facial skin, secondaryOutcomes measure: Tolerability of 4% imipramine on facial skin, secondaryOutcomes measure: Tolerability of 4% amitriptyline on facial skin, secondaryOutcomes measure: Tolerability of 4% amitriptyline on facial skin, secondaryOutcomes measure: Tolerability of 4% amitriptyline on facial skin, secondaryOutcomes measure: Tolerability of 4% amitriptyline on facial skin, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Wright State Physicians, status: RECRUITING, city: Fairborn, state: Ohio, zip: 45324, country: United States, contacts name: Pharmacology Translational Unit, role: CONTACT, phone: 937-245-7500, email: pturesearch@wrightstatephysicians.org, contacts name: Travers, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 39.82089, lon: -84.01938, hasResults: False
protocolSection identificationModule nctId: NCT06312800, orgStudyIdInfo id: LeWitt02, briefTitle: Acamprosate and Methazolamide for Essential Tremor, statusModule overallStatus: WITHDRAWN, startDateStruct date: 2016-03, primaryCompletionDateStruct date: 2017-06, completionDateStruct date: 2017-12, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Henry Ford Health System, class: OTHER, descriptionModule briefSummary: This is an investigator initiated study is designed to evaluate the anti-tremor benefits of two marketed medications, methazolamide and acamprosate in subjects with a diagnosis of essential tremor (ET)., conditionsModule conditions: Essential Tremor, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, enrollmentInfo count: 0, type: ACTUAL, armsInterventionsModule interventions name: Acamprosate, interventions name: Placebo, interventions name: Methazolamide, outcomesModule primaryOutcomes measure: Fahn-Marin-Tolosa rating scale (FMTRS) Part A, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Henry Ford West Bloomfield Hospital, city: West Bloomfield, state: Michigan, zip: 48322, country: United States, geoPoint lat: 42.56891, lon: -83.38356, hasResults: False
protocolSection identificationModule nctId: NCT06312787, orgStudyIdInfo id: VX23-118-002, briefTitle: A Study to Evaluate the Relative Bioavailability and Food Effect of a VX-118 Tablet Formulation, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-02, primaryCompletionDateStruct date: 2024-05, completionDateStruct date: 2024-05, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: Vertex Pharmaceuticals Incorporated, class: INDUSTRY, descriptionModule briefSummary: The purpose of this study is to evaluate the relative bioavailability, effect of food on the pharmacokinetic parameters, and safety and tolerability, of a tablet formulation of VX-118 in healthy participants., conditionsModule conditions: Cystic Fibrosis, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 15, type: ESTIMATED, armsInterventionsModule interventions name: VX-118, outcomesModule primaryOutcomes measure: Maximum Observed Plasma Concentration (Cmax) of VX-118, primaryOutcomes measure: Area Under the Concentration Versus Time Curve (AUC) of VX-118, secondaryOutcomes measure: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 55 Years, stdAges: ADULT, contactsLocationsModule locations facility: Celerion - Lincoln, status: RECRUITING, city: Lincoln, state: Nebraska, zip: 68502, country: United States, geoPoint lat: 40.8, lon: -96.66696, hasResults: False
protocolSection identificationModule nctId: NCT06312774, orgStudyIdInfo id: IRAS 333853, briefTitle: Feasibility of Proteomics in Chronic Lung Disease With Sarcopenia, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-18, primaryCompletionDateStruct date: 2025-11-07, completionDateStruct date: 2027-01-04, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: University College, London, class: OTHER, descriptionModule briefSummary: Sarcopenia, the loss of muscle mass and strength with ageing, is a prevalent condition in older adults, particularly those with chronic lung diseases like COPD and interstitial lung disease. The condition exacerbates the decline in physical ability, leading to decreased mobility, impaired quality of life, and increased disability. Sarcopenia's prevalence varies across populations, estimated to affect up to 10% of adults over 60 worldwide, with higher rates reported in studies employing consensus definitions of sarcopenia. The prevalence is even higher in patients with chronic lung diseases, reaching up to 26.6%. Sarcopenia's impact on health-related quality of life has been widely investigated. The condition is associated with various comorbidities, including chronic heart failure, obesity, diabetes, and chronic kidney disease, all negatively impacting the quality of life.The proposed study's primary aim is to assess the feasibility of the FACS (finding, assessing, confirming, severity) approach in determining sarcopenia's prevalence in the chronic lung disease population. FACS includes screening, strength measurements, and bioelectrical impedance analysis (BIA) to confirm sarcopenia.The study will also explore potential mechanisms associated with sarcopenia in this population, using proteome and single-cell transcriptome profiles. These multi-omics approaches provide a comprehensive view of the cellular and molecular changes underlying sarcopenia.In particular, the study will evaluate patient acceptance, time efficiency of each test, and recruitment effectiveness. The outcomes will guide the design and execution of subsequent, larger studies and provide preliminary data for power calculation for the full-scale study., conditionsModule conditions: Sarcopenia, conditions: Chronic Lung Disease, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 49, type: ESTIMATED, armsInterventionsModule interventions name: This is observational study, outcomesModule primaryOutcomes measure: Sarcopenia, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06312761, orgStudyIdInfo id: Oral T-12, briefTitle: Single-Dose Pharmacokinetics of Oral Testosterone Undecanoate With and Without Concomitant Inhibition of UGT2B17, acronym: OralT12, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-01, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: University of Washington, class: OTHER, collaborators name: Washington State University, descriptionModule briefSummary: This study will be performed in normal men whose endogenous testosterone production has been temporarily suppressed by the administration of a single dose of 120 mg of the oral GnRH antagonist Relugolix, which is approved for the treatment of prostate cancer, and can suppress endogenous testosterone biosynthesis for 48-72 hours after a single dose., conditionsModule conditions: Hypogonadism, Male, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: NON_RANDOMIZED, interventionModel: SINGLE_GROUP, primaryPurpose: HEALTH_SERVICES_RESEARCH, maskingInfo masking: NONE, enrollmentInfo count: 10, type: ESTIMATED, armsInterventionsModule interventions name: Relugolix 120Mg Tab, interventions name: Curcumin, interventions name: Testosterone Undecanoate 237 MG Oral Capsule, outcomesModule primaryOutcomes measure: average serum testosterone after dosing on day 2, primaryOutcomes measure: average serum testosterone after dosing on day 3, primaryOutcomes measure: Maximum concentration, primaryOutcomes measure: time to maximum concentration, primaryOutcomes measure: area-under-the curve, primaryOutcomes measure: elimination phase half-life, eligibilityModule sex: MALE, minimumAge: 18 Years, maximumAge: 55 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06312748, orgStudyIdInfo id: 138675, briefTitle: Novel Approaches for Improving Vascular Function in Veterans With HFpEF, statusModule overallStatus: RECRUITING, startDateStruct date: 2021-05-19, primaryCompletionDateStruct date: 2028-09-30, completionDateStruct date: 2030-09-30, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-21, sponsorCollaboratorsModule leadSponsor name: D. Walter Wray, class: OTHER, collaborators name: US Department of Veterans Affairs, descriptionModule briefSummary: This project will evaluate the impact of L-Citrulline, tetrahydrobiopterin (BH4), and atorvastatin administration on physical capacity and vascular function in Veterans with heart failure with preserved ejection fraction (HFpEF)., conditionsModule conditions: HFpEF - Heart Failure With Preserved Ejection Fraction, conditions: Inflammation, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, maskingDescription: A block randomization method will be used to randomize participants into equal groups and will be handled by investigational pharmacist., whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, enrollmentInfo count: 90, type: ESTIMATED, armsInterventionsModule interventions name: L-Citrulline, interventions name: Placebo for L-Citrulline, interventions name: BH4, interventions name: Placebo for BH4, interventions name: Atorvastatin, interventions name: Placebo for Atorvastatin, outcomesModule primaryOutcomes measure: Flow-mediated dilation (FMD), secondaryOutcomes measure: Passive Limb Movement (PLM), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: George E. Whalen VA Medical Center, status: RECRUITING, city: Salt Lake City, state: Utah, zip: 84128, country: United States, contacts name: Walter Wray, role: CONTACT, phone: 858-205-3078, email: walter.wray@hsc.utah.edu, geoPoint lat: 40.76078, lon: -111.89105, hasResults: False
protocolSection identificationModule nctId: NCT06312722, orgStudyIdInfo id: PR1309, briefTitle: Safety and Effectiveness of the Optilume® BPH Catheter System in a Post-Market Study, acronym: PEAK, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-07, primaryCompletionDateStruct date: 2031-02-07, completionDateStruct date: 2031-02-07, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Urotronic Inc., class: INDUSTRY, descriptionModule briefSummary: The goal of this clinical trial is to verify the continued safety and effectiveness for the Optilume BPH Catheter System., conditionsModule conditions: Benign Prostatic Hyperplasia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Prospective, single-arm, multi-center, post market clinical trial, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 92, type: ESTIMATED, armsInterventionsModule interventions name: Optilume® BPH Catheter System, outcomesModule primaryOutcomes measure: The primary efficacy endpoint is the average IPSS improvement from baseline to 12 months., secondaryOutcomes measure: Semen Sub-Study Safety Secondary Endpoint, eligibilityModule sex: MALE, minimumAge: 50 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Urotronic, INC, status: RECRUITING, city: Plymouth, state: Minnesota, zip: 55441, country: United States, contacts name: Jill Moland, role: CONTACT, email: jmoland@laborie.com, contacts name: Brandon Shuler, role: CONTACT, email: bshuler@laborie.com, geoPoint lat: 45.01052, lon: -93.45551, hasResults: False